Skip to main content
Richard Gaynor, MD, Oncology, Indianapolis, IN

RichardBrianGaynorMD

Oncology Indianapolis, IN

Vice president oncology Eli Lilly

Dr. Gaynor is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Gaynor's full profile

Already have an account?

Education & Training

  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1978 - 1980
  • University of Texas Southwestern Medical Center
    University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1975 - 1978
  • University of Texas Southwestern Medical School
    University of Texas Southwestern Medical SchoolClass of 1975

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1978 - Present
  • TX State Medical License
    TX State Medical License 1975 - 2025
  • IN State Medical License
    IN State Medical License 2002 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Elected Member The American Society for Clinical Investigation, 1988

Publications & Presentations

PubMed

Press Mentions

  • Neon Therapeutics Submits European Clinical Trial Authorization Application for Personal Neoantigen-Targeted T Cell Therapy NEO-PTC-01
    Neon Therapeutics Submits European Clinical Trial Authorization Application for Personal Neoantigen-Targeted T Cell Therapy NEO-PTC-01December 18th, 2019
  • Neon Therapeutics Announces New Strategic Focus on Novel T Cell Programs
    Neon Therapeutics Announces New Strategic Focus on Novel T Cell ProgramsNovember 20th, 2019
  • Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific Neoantigens
    Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific NeoantigensSeptember 5th, 2019
  • Join now to see all

Grant Support

  • Inhibition Of NFKB Pathway On Growth Of Colon CarcinomaNational Cancer Institute2001–2002
  • Mechanisms Regulating HIV-1 Gene ExpressionNational Institute Of Allergy And Infectious Diseases2001
  • Cellular Proteins Involved In HIV1 TAR RNA FunctionNational Institute Of Allergy And Infectious Diseases1999–2001
  • Properties Of The HTLV I Tax ProteinNational Cancer Institute1998–2000
  • TAT Associated Kinase Regulation Of HIV Gene ExpressionNational Institute Of Allergy And Infectious Diseases1997–2000
  • Novel Treatment Of Brain TumorsNational Cancer Institute1997–2000
  • HIV 1 LTR Regulatory ElementsNational Institute Of Allergy And Infectious Diseases1995–1999
  • Cellular Proteins Involved In HIV 1 TAR RNA FunctionNational Institute Of Allergy And Infectious Diseases1994–1998
  • Properties To The HTLV I Tax ProteinNational Cancer Institute1997
  • Transdominant TAT Mutants Inhibit HIV Gene ExpressionNational Institute Of General Medical Sciences1996
  • Adenovirus E1A Protein Interaction With Cellular FactorsNational Cancer Institute1993–1996
  • Regulation Of HIV Gene ExpressionNational Institute Of Allergy And Infectious Diseases1991–1994
  • Cellular And Viral Proteins And HIV RegulationNational Institute Of Allergy And Infectious Diseases1991–1993
  • Transcriptional Regulation By The Adenovirus EIA ProteinNational Cancer Institute1991–1992
  • Transcriptional Regulation By The Adenovirus E1A ProteinNational Cancer Institute1988–1991
  • Regulation Of HIV Gene ExpressionNational Institute Of Allergy And Infectious Diseases1990
  • Cellular And Viral Proteins And HIV RegulationNational Institute Of Allergy And Infectious Diseases1989–1990
  • Cellular Proteins Which Regulate HIV Gene ExpressionNational Institute Of Allergy And Infectious Diseases1987–1989
  • Transforming Functions Of Adenovirus EIA ProteinsNational Cancer Institute1985–1986